Skip to main content
Diabetes, Metabolic Syndrome and Obesity logoLink to Diabetes, Metabolic Syndrome and Obesity
. 2017 Aug 14;10:345–361. doi: 10.2147/DMSO.S100074

Novel biomarkers for prediabetes, diabetes, and associated complications

Brenda Dorcely 1, Karin Katz 1, Ram Jagannathan 2, Stephanie S Chiang 1, Babajide Oluwadare 1, Ira J Goldberg 1, Michael Bergman 1,
PMCID: PMC5565252  PMID: 28860833

Abstract

The number of individuals with prediabetes is expected to grow substantially and estimated to globally affect 482 million people by 2040. Therefore, effective methods for diagnosing prediabetes will be required to reduce the risk of progressing to diabetes and its complications. The current biomarkers, glycated hemoglobin (HbA1c), fructosamine, and glycated albumin have limitations including moderate sensitivity and specificity and are inaccurate in certain clinical conditions. Therefore, identification of additional biomarkers is being explored recognizing that any single biomarker will also likely have inherent limitations. Therefore, combining several biomarkers may more precisely identify those at high risk for developing prediabetes and subsequent progression to diabetes. This review describes recently identified biomarkers and their potential utility for addressing the burgeoning epidemic of dysglycemic disorders.

Keywords: prediabetes, biomarkers, inflammatory markers, diabetes, diabetes complications

Introduction

Prediabetes is defined as an intermediate state with plasma glucose levels ranging between normoglycemia and diabetes. The Centers for Disease Control estimated that in 2012 about 86 million, or one out of three, adults had prediabetes in the US.1 However, 90% of these individuals were unaware of their diagnosis. In 2015, the International Diabetes Federation estimated that the worldwide prevalence of impaired glucose tolerance (IGT) in adults was 318 million and expected to reach 482 million by 2040.2 The annual progression rate to diabetes is 5–10%,3 with older individuals, those with severe insulin resistance (IR), low insulin secretion, and other diabetes risk factors even more likely to progress.4 How can we identify patients with prediabetes and what can we do to prevent progression to diabetes?

Lifestyle and pharmacological interventions have been most effective in preventing progression to diabetes and associated complications. Preservation of β-cell function and reduction in IR and diabetes complications such as retinopathy, cardiovascular disease (CVD), and all-cause mortality were observed subsequent to lifestyle modification.5,6 The Da Qing Diabetes Study in China,6 the Finnish Diabetes Prevention Study,7,8 and the U.S. Diabetes Prevention Program3,9 have shown that changes in dietary habits, weight loss, and increased physical activity reduced the risk of progression to diabetes. Bariatric surgery promotes weight loss and is beneficial in prediabetes.10

Identification of risk and diagnosis of prediabetes

Development of prediabetes involves multiple factors including genetics, peripheral IR, defects in insulin secretion, glucotoxicity, lipotoxicity, impaired incretin release, amylin accumulation, inflammation, oxidative stress, and decreased β-cell mass leading to β-cell dysfunction.1113 Prediabetes is classified as isolated impaired fasting glucose (IFG) or IGT.14 Glucose and glycated hemoglobin (HbA1c) criteria for diagnosing dysglycemic states are controversial as there are differing thresholds recommended by the American Diabetes Association (ADA) and the World Health Organization.15,16 We will review several additional biomarkers used to predict the risk of progression to diabetes.

Diagnostic biomarkers and their clinical utility

Hemoglobin A1c

HbA1c is the most commonly used biomarker to diagnose prediabetes and diabetes. HbA1c forms when glucose attaches to the amino-terminal group of the β subunit of hemoglobin.17 HbA1c reflects chronic glycemia rather than glucose levels at a single time point. Currently, the ADA criteria for diabetes are HbA1c ≥6.5% (48 mmol/mol) and 5.7–6.4% (39–46 mmol/mol) for prediabetes.14 Increased HbA1c levels are associated with increased morbidity and mortality. In the Norfolk prospective study, higher HbA1c levels were also associated with increased CVD, cancer, and all-cause mortality.18 Long-term prospective studies, including the Diabetes Control and Complications Trial, the UK Prospective Diabetes Study Group, and the Epidemiology of Diabetes Interventions and Complications study have shown that diabetic complications are directly related to the mean HbA1c, with a level ≥6.5% (48 mmol/mol) associated with retinopathy.1921 Additionally, HbA1c was more strongly correlated with retinopathy than fasting plasma glucose (FPG). Thus, HbA1c may be a better predictor of microvascular complications than FPG.22

HbA1c has several advantages versus FPG and oral glucose tolerance test (OGTT) including greater convenience as fasting is not required, greater pre-analytical stability, and less day-to-day perturbation during periods of stress and illness.23 Since HbA1c reflects chronic exposure to glucose, it is particularly useful for lifestyle modification counseling.23,24 However, there is conflicting evidence regarding the usefulness of HbA1c as it provides moderate sensitivity in diabetes diagnosis when compared to OGTT and FPG (Table 1).23,24 OGTT is more strongly correlated with IR and secretion than HbA1c,25 which is expected since the response to a high dose of glucose would more accurately reflect an individual’s physiologic response and insulin secretion and actions. For this reason, HbA1c and OGTT levels may be discrepant as individuals classified as having prediabetes according to OGTT results may be normoglycemic by HbA1c standards.

Table 1.

Characteristics of biomarkers for prediabetes, diabetes, and associated complications

Traditional biomarkers
Biomarker Mechanism of action Sensitivity and specificity Advantages Disadvantages Association with dysglycemia
1. HbA1c HbA1c forms when glucose attaches to the amino-terminal group of the β subunit of hemoglobin17 Diabetes28
When HbA1c≥6.5% compared to FPG
FPG≥126 mg/dL (7.0 mmol/L) and 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L)
Sensitivity: 0.589
Specificity: 0.960
Prediabetes28
HbA1c ≥5.7, <6.5 for prediabetes
Sensitivity: 0.354
Specificity: 0.834
Increased HbA1c levels are associated with increased morbidity and mortality18
More reliable biomarker of chronic glycemia
HbA1c correlates with greater convenience,
greater pre-analytical stability, and less day-to-day perturbation during periods of stress and illness23
HbA1c has moderate sensitivity in diagnosing diabetes when compared to OGTT and FPG2426
No consensus which cut-off points for HbA1c would be most sensitive2629
HbA1c threshold for prediabetes does not consider ethnicity, BMI, and age, all of which may significantly alter HbA1c levels30,31
HbA1c is not always a reliable measure of average circulating glucose levels40
Changes in the production rate or circulating life span of red blood cells affect HbA1c levels, as well as hemoglobin variants such as HbS, HbC, HbD, and HbE36,39
HbA1c is a reflection of chronic glycemia17
2. FA FA is a ketoamine created by glycosylation of total serum proteins, primarily albumin41 Diabetes38
2.5 mmol/L for diabetes (FPG >7 mmol/L or HbA1c≥6.5%)
Sensitivity: 0.82
Specificity: 0.94
Prediabetes38
Limited data
FA reflects average
blood glucose concentration over the previous 1–4 weeks38
FA is especially beneficial in conditions that affect hemoglobin status or rate of erythrocyte turnover52
FA is cost-effective, simple, and convenient, as it does not require fasting42,43
FA has higher within-subject variation and falsely low levels in conditions leading to rapid albumin turnover44
Not all studies have found that mean serum FA levels are useful for prediabetes screening37,38,41,47
FA increases in states of high glucose concentrations41
3. GA Glycosylation of albumin and measured by the ratio of GA to total albumin Diabetes50
When GA is ≥15.5%
Sensitivity: 0.83
Specificity: 0.83
Prediabetes49
When GA >13.35% for prediabetes
Sensitivity: 0.41
Specificity: 0.71
The combination of GA with HbA1c can predict prediabetes with greater sensitivity than HbA1c alone49
GA is a superior index of glycemic control than HbA1c in patients with renal failure, hemolytic anemia, and those receiving blood transfusions41
GA is preferred over FA in clinical conditions that result in protein loss such as nephrotic syndrome, liver disease, and thyroid disease41
GA may be artificially low in individuals with increased BMI, body fat mass, and visceral adiposity53
Inaccurate when there are changes in albumin turnover
Falsely lower levels in obesity52
Serum GA is associated with prediabetes and diabetes49
4. OGTT Measures fasting and 2-hour plasma glucose levels Diabetes
Sensitivity: 0.93155
Prediabetes
Sensitivity: 0.811155
OGTT is more strongly correlated with IR and secretion than HbA1c25
OGTT provides important information with regard to risk that HbA1c or FPG cannot4
OGTT is variable, invasive, and time consuming
It is inconvenient because it requires fasting and shows day-to-day perturbation during periods of stress and illness
Elevated FPG and 2-hour levels are associated with prediabetes and diabetes
5. 1, 5 AG 1,5 AG is a dietary monosaccharide. Plasma concentrations are inversely correlated with plasma glucose 60 Diabetes47
When 1,5 AG <17 mcg/mL for diabetes defined by optimal HbA1c >6% cutoff
Sensitivity: 0.96
Specificity: 0.88
Prediabetes62
Data not available
1,5 AG is a useful biomarker as it reflects glucose levels within the past 10–14 days
It is stable, replicable, and less costly compared to other glycemic diagnostic tests61
Plasma 1,5 AG levels can change based on dietary habits, sex, and race64,65
Levels are also affected by renal hemodynamics or treatment with SGLT2 inhibitors66,67
Plasma 1,5 AG levels are lowered in subjects with prediabetes and diabetes compared with subjects with normoglycemia
Novel biomarkers
Biomarker Mechanism of action Association with dysglycemia and complications
6. Adiponectin Adiponectin is derived from adipose tissues and exhibits insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties. It is an independent predictor of diabetes68 Lower levels of adiponectin are associated with increased IR and obesity, while higher levels have been related to lifestyle intervention groups in diabetes prevention trials68
Adiponectin levels are inversely related to the risk of incident prediabetes, independent of ethnic or sex differences69
Adiponectin levels were directly correlated with insulin sensitivity and indirectly correlated with insulin secretion69
7. FetA FetA is a hepatic secretory glycoprotein that has been proposed to promote lipid-induced IR through the TLR4-inflammatory signaling pathway, resulting in production of inflammatory cytokines71 FetA correlates with increased risk of developing T2DM and associated complications70
8. α-HB α-HB is an organic acid byproduct produced during the synthesis of α-KB, a product of amino acid catabolism (threonine and methionine) and glutathione anabolism (cysteine formation pathway) in hepatic tissue156 IR, increased oxidative stress, and lipid oxidation may cause chronic shifts in glutathione synthesis leading to elevated α-HB levels88
α-HB was found to be significantly associated with IR independent of sex, age, BMI, and collection site76
IR was associated with reductions in glycine and serine, which are upstream of α-KB
9. L-GPC L-GPC is a metabolite formed by the enzyme phospholipase A2 in the liver and by lecithin-cholesterol acyltransferase in the circulation. Phospholipase A2 activity is increased during inflammation76,92,93 L-GPC is a negative predictor of T2DM progression76,93
10. Lp(a) Lp(a) is a lipoprotein subclass that contributes to atherogenesis94 Lp(a) has an inverse relationship with prevalence of prediabetes and T2DM95
11. Triglycerides Esters derived from glycerol and three fatty acids Associated with β-cell dysfunction and reduced insulin secretion in subjects with prediabetes94,96
12. HDL A major lipoprotein HDL-C promotes insulin secretion
• Low HDL-C concentration may lead to progression from prediabetes to diabetes
• Increased proportion of small HDL3 over HDL-C in subjects with prediabetes
• Decreased proportion of HDL-LpPLA2 in prediabetes97
13. Ceramide Lipid molecules Positively associated with prediabetes and T2DM85,98
14. Ferritin and transferrin Ferritin is an intracellular protein that stores and releases iron Elevated serum ferritin and transferrin saturation have been strongly associated with increased risk of prediabetes and diabetes. Iron has properties that contribute to IR such as production of highly active radical formation, damage to DNA and cell membrane integrity, β-cell oxidative stress leading to decreased insulin secretory capacity, and interference with glucose uptake in skeletal muscles and adipocytes. Moreover, catalytic iron stimulates the formation of reactive oxidative species, hepatic dysfunction, and β-cell apoptosis, all of which contribute to IR103106
15. MBL-associated serine proteases MBL-associated serine proteases are important enzymes for innate immune responses and activation of the lectin pathway of the complement system108 MASP1 has been shown to positively correlate with prediabetes, diabetes, and CVD109
16. THBS1 THBS1 directs formation of multiprotein complexes that modulate cellular phenotype (e.g., stimulates/inhibits migration of vascular smooth muscle cells or endothelial cells, respectively)110 THBS1 positively associated with:109
• Higher prediabetes prevalence
• Increased IR
• Increased 2-hour glucose
• Adipose inflammation and metabolic dysregulation in obesity and type 2 diabetes
17. GPLD1 GPLD1 has a postulated role in the insulin-mimetic signaling pathway of glycosylphosphatidylinositol compounds, though the exact mechanism is not known
GPLD1 cleavage generates second messengers that can act as inulin-mimetic molecules109
GPLD1 positively associated with:109
• Type 2 diabetes and prediabetes (less strongly)
• MASP1, another novel prediabetes biomarker
• HDLs in serum
18. Acyl-carnitine Acyl-carnitines interact with NF-Kβ, which promotes inflammation and IR
The precise role acyl-carnitines play has not yet been elucidated118
Elevated levels of acyl-carnitine found in individuals with prediabetes
Associated with inflammation and IR116,117
19. miRNA miRNAs are involved in cell growth, differentiation, proliferation, and death
Specific miRNAs124,126
miR-192 regulates the tumor protein p53
miR-193b involved in brown adipocyte differentiation and inflammation reduction
miR-15a thought to directly inhibit uncoupling protein-2 gene expression, leading to increased oxygen consumption and reduced ATP generation, thus promoting insulin synthesis
Others thought to play a role in β-cell function100
Many miRNAs have been found to be elevated in individuals with prediabetes122
miR-192 and 193b associated with subjects with IFG and IGT; associated with high triglyceride levels and fatty liver index120
Other miRNAs play a role in insulin production, secretion, and regulation126
Inflammatory biomarkers
Biomarker Mechanism of action Association with dysglycemia and complications
20. CRP Derived from IL-6-dependent hepatic biosynthesis
Primary marker of acute phase response131
Associated with type 2 diabetes and IR
Found to be associated with prediabetes
CRP found more elevated in subjects who had prediabetes and IR than those with prediabetes but insulin sensitive108
21. IL-6 IL-6 cytokines exhibit immunoregulatory actions and are involved in glucose homeostasis and metabolism through action on pancreatic β cells,157 adipocytes, hepatocytes, and skeletal muscles158 Associated with type 2 diabetes and IR131
22. WBCs WBC count is a marker of immunity and inflammation140
NLR is an indicators of subclinical inflammation and microvascular and macrovascular complications in diabetes142,143
WBC count has been predictive of:
• Worsening insulin action
• Secretory function and T2DM
• Coronary heart disease
• Higher 1-hour post-load glucose level140
23. Fibrinogen Fibrinogen actions affect blood viscosity, platelet aggregation, and fibrin formation Fibrinogen associated with:
• Prediabetes and weakly associated with diabetes
• Higher 1-hour post-load glucose level atherosclerosis134
24. PAI-1 Marker of reduced fibrinolysis
Decreased activity leads to defective coagulation147,148
Independent predictor of diabetes147
25. IL-18 IL-18 increases during hyperglycemia149 Associated with increased risk of T2DM
Increased IL-18 correlated with progression from prediabetes to diabetes149
26. IL-1RA IL-1RA is an anti-inflammatory marker elevated when IL-1 pathway induced by glucose and free fatty acids during overfeeding150 Associated with:
• Decreasing insulin sensitivity
• Temporary increasing β-cell function
• Elevated in prediabetes and diabetes151

Abbreviations: HbA1c, hemoglobin A1c; FPG, fasting plasma glucose; BMI, body mass index; FA, fructosamine; GA, glycated albumin; OGTT, oral glucose tolerance test; IR, insulin resistance; 1, 5 AG, 1, 5 anhydroglucitol; FetA, fetuin-A; TLR4, toll-like receptor 4; T2DM, type 2 diabetes mellitus; α-HB, alpha-hydroxybutyrate; α-KB, α-ketobutyrate; L-GPC, L-alpha glycerylphosphorylcholine; Lp(a), lipoprotein(a); HDL-C, high-density lipoprotein cholesterol; HDL-LpPLA2, HDL-associated lipoprotein-associated phospholipase A2; MBL, mannose binding lectin; CVD, cardiovascular disease; THBS1, thrombospondin 1; GPLD1, glycosylphosphatidylinositol-specific phospholipase D1; NF-Kβ, nuclear factor-κB; miRNA, microRNA; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; CRP, C-reactive protein; IL, interleukin; WBC, white blood cell; NLR, neutrophil-lymphocyte ratio; PAI-1, plasminogen activator inhibitor-1; IL-1RA, IL-1 receptor antagonist; SGLT2, sodium-glucose co-transporter 2.

Moreover, it is not clear which cut points for HbA1c would be most sensitive. Utilizing ADA criteria, HbA1c may miss individuals with prediabetes despite levels <5.5% (37 mmol/mol).26 The NHANES and Screening for Impaired Glucose Tolerance studies demonstrated that only 60–70% of subjects had normal glucose tolerance (NGT) when HbA1c levels were <5.7% (39 mmol/mol).2729 In addition, the HbA1c threshold for prediabetes does not consider ethnicity, body mass index (BMI), and age, all of which may significantly alter HbA1c levels.3033 For example, HbA1c levels are higher among African Americans, Hispanics, and Asian/Pacific Islanders compared to non-Hispanic whites. One study demonstrated that HbA1c is 0.3% higher in black men and 0.4% higher in black women.34 As a result, standard classification ranges may misdiagnose some individuals from certain ethnic groups with prediabetes, thus overestimating the prevalence of prediabetes.

HbA1c is not always a reliable measurement of average circulating glucose levels. HbA1c has a life span related to the half-life of the red blood cell ranging from 90 to 120 days.35 Therefore, changes in the production rate or circulating life span of red blood cells will affect HbA1c levels; for example, reduced production leads to a greater percent of older cells, whereas more rapid turnover reduces the average time during which the red cells are exposed to hyperglycemia.36 Several clinical conditions may result in overestimation or underestimation of HbA1c levels. Conditions in which HbA1c is falsely elevated include iron deficiency anemia, asplenia, folate and vitamin B-12 deficiency, severe hyper-triglyceridemia, and uremia.36 Falsely low HbA1c occurs in hemolytic anemia, blood loss,37,38 splenomegaly, and end-stage renal disease.36 Hemoglobin variants, such as HbS, HbC, HbD, and HbE,39 may also result in overestimation or under-estimation of HbA1c, depending on which method is used.36 For these reasons, HbA1c alone can be inadequate for diagnosing prediabetes, and more accurate diagnosis may require confirmation with other biomarkers.40

Fructosamine

Fructosamine (FA) has been used as an alternate glycemic marker for diabetes screening and may be potentially useful for diagnosing prediabetes. FA is a ketoamine created by glycosylation of total serum proteins, primarily albumin.41 FA increases in states of high glucose concentrations. Since it reflects average blood glucose concentrations over the previous 1–4 weeks,38 it can be a useful clinical marker of short-term glycemic fluctuation and glucose control.38,52 FA is especially useful in conditions that affect hemoglobin reliability, as already described, and has moderate sensitivity and high specificity (Table 1).52 Other advantages of FA include cost-effectiveness and convenience, as its measurement does not require fasting.42,43

Limitations of FA include higher within-subject variability and falsely low levels when conditions leading to rapid albumin turnover are present such as nephrotic syndrome and liver disease.44 There are conflicting data regarding its efficacy as a biomarker for prediabetes. Several studies found that FA correlates with hyperglycemia and HbA1c levels in both type 1 diabetes mellitus and type 2 diabetes mellitus (T2DM).41,45,46 FA may also indicate the risk for developing microvascular complications.45 However, not all studies have found that mean serum FA levels are useful for prediabetes screening.37,38,41,4749

Thus, FA could be a valuable complementary marker in clinical conditions where HbA1c may be inaccurate. However, as the literature concerning FA is limited, and studies included small or niche patient cohorts, there are insufficient data to conclude its role as an alternate biomarker for microvascular complications.

Glycated albumin

Similar to FA, glycated albumin (GA) has been found to be a superior index of glycemic control than HbA1c in patients with renal failure, hemolytic anemia, and those receiving blood transfusions.41,45 FA refers to all glycated serum proteins, which includes GA. Therefore, as FA is not corrected for albumin or total protein concentration, FA levels can fluctuate in certain conditions such as liver disease. Alternatively, GA measures the ratio of GA to total albumin.50 Thus, GA is preferred to FA in clinical conditions that result in protein loss such as nephrotic syndrome, liver, and thyroid disease.50 While it is unclear whether FA should be corrected for total serum protein concentration, one study described an improvement in the correlation of FA with HbA1c when serum FA was corrected for albumin.46,51

Serum GA levels of 15–16% in Asian populations were associated with diabetes.52,53 Furthermore, GA has moderate sensitivity and specificity for diagnosing prediabetes and diabetes (Table 1). However, combining FPG <100 mg/dL (5.56 mmol/L) with serum GA <15% to exclude diabetes, and FPG ≥126 mg/dL (7.0 mmol/L) or serum GA ≥17% to diagnose diabetes, increased the sensitivity of GA. There are no clear threshold values for FA and GA for prediabetes but one study used a level ≥230 μmol/L for FA and ≥13.35% for GA, both of which correlated with HbA1c of 5.7% (39 mmol/mol) for detecting prediabetes.49 GA as well as FA is associated with CVD, ischemic stroke, retinopathy, chronic kidney disease, and death in the Atherosclerosis Risk in Communities Study.51,54 These associations were similar to those of HbA1c,54 suggesting that FA and GA may be useful alternative biomarkers in clinical conditions where HbA1c is inaccurate.51 The combination of GA with HbA1c was shown to predict prediabetes with greater sensitivity than HbA1c alone.49 In addition, GA may be superior to FA for detecting prediabetes, whereas the combination of FA with HbA1c was not superior to HbA1c alone.47,49,50,55

There are conditions in which GA may be inaccurate due to changes in albumin turnover. For example, the lower GA levels observed in obesity may be due to increased albumin catabolism and decreased rate of albumin synthesis from obesity-associated inflammation. However, the precise mechanism for the lower GA in obesity is unclear.52,53,5658 GA may be artificially low in individuals with increased BMI, body fat mass, and visceral adiposity.53 The mechanism for alterations in GA levels in these conditions is not well understood.59

1,5 Anhydroglucitol

1,5 Anhydroglucitol (1,5 AG), a dietary monosaccharide, has been suggested as a prediabetes marker. As the proximal tubules in the kidney have a greater affinity for glucose than 1,5 AG, high glucose levels prevent 1,5 AG reabsorption resulting in elevated 1,5 AG urinary excretion. Therefore, plasma 1,5 AG concentrations are inversely correlated with plasma glucose levels60 demonstrated in a study in which the 1,5 AG level was highest in the control group followed by the prediabetes and diabetes groups, respectively.60 Some studies, but not all, have found an inverse relationship between 1,5 AG and OGTT 2-hour post-glucose levels.61,62 Studies have also shown an inverse relationship between 1,5 AG and HbA1c as well as FPG levels.63

Similar to FA, 1,5 AG may be a useful biomarker as it reflects glucose levels within the preceding 10–14 days.61 1,5 AG is stable, reproducible, and less costly when compared to other glycemic diagnostic tests.61 It may be useful for identifying postprandial glycemic excursions and individuals at risk of complications as 1,5 AG has been associated with retinopathy and microvascular and macrovascular events in diabetes. However, it is unclear if 1,5 AG is superior to HbA1c. Plasma 1,5 AG levels can change based on diet, sex,64,65 and race. Levels are also affected by renal hemodynamics or treatment with sodium-glucose co-transporter 2 inhibitors.66,67 There is no consensus on the use of 1,5 AG as a prediabetes screening tool.65,66

Adiponectin

Adiponectin, derived from adipose tissue, exhibits insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties and is an independent predictor of diabetes.68 Lower levels of adiponectin are associated with increased IR and obesity, while higher levels have been related to lifestyle intervention groups in diabetes prevention trials.68 The association of adiponectin with diabetes risk appears to be evident at a much earlier stage in the progression to diabetes; more specifically, lower adiponectin levels were observed a decade before diabetes was diagnosed, particularly in men.68 Additionally, in offspring of parents with T2DM, baseline adiponectin levels are inversely related to the risk of incident prediabetes independent of ethnic or sex differences.69 Using the hyperinsulinemic euglycemic clamp and intravenous glucose tolerance test, adiponectin levels were directly correlated with insulin sensitivity and indirectly with insulin secretion.69

Fetuin-A

Fetuin-A (FetA) is a hepatic secretory glycoprotein that correlates with increased risk of developing T2DM and associated complications.70 Importantly, unlike adiponectin, the EPIC-Potsdam prospective cohort study found that FetA was independently associated with T2DM after controlling for BMI and waist circumference.70 FetA has been proposed to promote lipid-induced IR through the toll-like receptor 4 (TLR4)-inflammatory signaling pathway, which results in production of inflammatory cytokines.71 As chronic inflammation induced by free fatty acids (FFAs) has been thought to result in IR, the FFA-TLR4 signaling pathway has been recognized as a cause of IR. However, FFA may not bind directly to TLR4. Pal et al showed that FetA binds to TLR4, and regulates insulin sensitivity through this interaction.71 High-fat diet-fed FetA knockdown mice have less TLR4-mediated inflammatory signaling in adipose tissue and IR, whereas intravenous injection of FetA in this model induced inflammatory signaling and IR. FFA-induced inflammatory cytokine expression in adipocytes occurred only in the presence of both FetA and TLR4; removing either prevented FFA-induced IR. FFAs did not produce IR in adipocytes with mutated TLR4 or galactoside-cleaved FetA. FetA, TLR4, interleukin (IL)-6, and tumor necrosis factor (TNF)-α were elevated in obese subjects with diabetes, suggesting an association between lipids, FetA concentrations, and TLR4 expression with IR.

Studies of the association between FetA concentration and CVD have been conflicting. No association,72 a positive association,73 or an inverse association have been reported. However one multi-ethnic US study found a positive trend in those with IFG or diabetes.74 FetA may be associated with higher risk of CVD in those susceptible to the development of IR.74

Taken together, these findings suggest that FetA is an endogenous ligand for TLR4 through which lipids induce IR. FetA may therefore serve as a novel therapeutic target for IR.

Metabolites and microRNA

Amino acids

Felig et al found that fasting branched chain and aromatic amino acids correlated with obesity and serum insulin, whereas glucose loading decreased amino acid levels in insulin-sensitive individuals but not in insulin-resistant individuals.75 This is likely due to insulin-mediated inhibition of proteolysis by skeletal muscle. More recent studies have demonstrated a correlation between amino acids and prediabetes, IR, and obesity.76 Branched chain amino acids (BCAAs), isoleucine, leucine, valine, tyrosine, as well as aromatic amino acid phenylalanine and glycine have been significantly associated with diabetes risk.75,7780 In addition, glutamine, methionine, cysteine, and 2-aminoadipic acid are increased in insulin-resistant states.8183 By contrast, glycine levels are decreased in individuals with prediabetes.8486 To further support this, a comprehensive systematic review and meta-analysis demonstrated positive associations with BCAAs and aromatic amino acids and inverse associations with glycine and glutamine with risk of T2DM.85 Alterations in circulating amino acid levels may represent a significant predictive biomarker for IR and T2DM.

α-Hydroxybutyrate

α-Hydroxybutyrate (α-HB) is an organic acid byproduct produced during the synthesis of α-ketobutyrate (α-KB), a product of amino acid catabolism (threonine and methionine) and glutathione anabolism (cysteine formation pathway) in hepatic tissue.76 The formation of α-KB is catalyzed by lactate dehydrogenase and α-HB. During oxidative stress, the rate of hepatic glutathione synthesis increases, resulting in increased production of α-KB.85,87 This causes a decrease in the availability of L-cysteine for glutathione synthesis and an elevation in α-HB. Thus, in IR, increased oxidative stress and lipid oxidation may cause chronic shifts in glutathione synthesis leading to elevated α-HB levels.88,89 This is demonstrated by increased urinary α-HB excretion in IR.90

Using α-HB as a biomarker, previous studies were able to distinguish NGT-insulin-sensitive (NGT-IS) subjects from IGT and IFG subjects and NGT-IS subjects from those with NGT-IR. Furthermore, using multiple logistic regression analyses, α-HB was found to be significantly associated with IR, independent of sex, age, BMI, and collection site.76 Furthermore, IR was associated with reductions in glycine and serine, which are upstream of α-KB, and an elevation in cysteine. The underlying mechanism may be related to redox imbalance with IR resulting in an increase in α-HB. α-HB may be an effective biomarker for prediabetes.76,89

Linoleoyl-glycerophosphocholine

Choline-containing phospholipids and sphingomyelins have been associated with increased risk of T2DM. Linoleoyl-glycerophosphocholine (L-GPC) was investigated in the Relationship Between Insulin Sensitivity and Cardiovascular Disease study.91 L-GPC is formed by hepatic phospholipase A2 and circulatory lecithin-cholesterol acyltransferase. Phospholipase A2 activity is increased with inflammation. L-GPC may inhibit phospholipase A2 through noncompetitive enzyme inhibition, thereby exhibiting anti-inflammatory properties.76,92 Thus, L-GPC is a negative predictor of T2DM progression in contrast to α-HB, a positive predictor.76,93

Lipoprotein(a)

Lipoprotein(a) [Lp(a)] is synthesized by the liver. Elevated levels of LP(a) are an independent risk factor for developing CVD.94 An inverse relationship between serum Lp(a) and the prevalence of prediabetes and T2DM has been reported, although the mechanism for the relationship between serum Lp(a) and T2DM is not clear.95 Insulin may play a role in reducing Lp(a) levels.95

Triglycerides and high-density lipoprotein

Elevated serum triglyceride (Tg) levels have been associated with β-cell dysfunction and reduced insulin secretion in prediabetes.94 Mechanistically, hypertriglyceridemia reduces glucose-induced insulin secretion through the glucose-fatty acid cycle, and promotes β-cell apoptosis by stimulating the production of ceramide and nitric oxide.96 Also, elevated Tg levels can cause lipotoxicity by accumulating within pancreatic β cells.94,96

Cholesteryl ester transfer protein mediates the exchange of lipids from Tg-rich lipoproteins with high-density lipoprotein (HDL). Increased Tg levels in insulin-resistant states accelerate this exchange.97 Then, the Tg in HDL cholesterol (HDL-C) are hydrolyzed by hepatic lipase, resulting in smaller HDL-C particles. ATP-binding cassette transporter A (ABCA1) mediates the efflux of cholesterol to small HDL3 particles.97 Subjects with prediabetes have significantly increased levels of small HDL3 particles compared with HDL-C levels.97 The proportion of small HDL3 particles is positively associated with Tg and negatively associated with HDL-C.97 In contrast to Tg, HDL-C promotes insulin secretion through its interaction with ABCA1. Low HDL-C concentrations may also lead to progression to diabetes from prediabetes. However, it is unclear if HDL-C levels are associated with β-cell dysfunction.96

Lipoprotein-associated phospholipase A2 (LpPLA2) is an enzyme that degrades oxidatively fragmented phospholipids and may play a role in atherogenesis.97 Individuals with IFG have significantly decreased HDL-associated LpPLA2 (HDL-LpPLA2) activity compared with subjects with normoglycemia. Low-density lipoprotein-associated LpPLA2 may exert pro-inflammatory effects, whereas HDL-LpPLA2 may have an atheroprotective role.97 Increased levels of small HDL3 particles and decreased activity of the anti-atherogenic HDL-LpPLA2 were found in subjects with IFG.97 Thus, subclasses of HDL-C may play a role in the pathogenesis of prediabetes.

Ceramide

In addition to Tg, ceramides have a positive association with prediabetes and T2DM.85,98 Ceramides are lipid molecules that mediate IR.99,100 Studies have shown that ceramides inhibit insulin action by decreasing phosphorylation and activation of Akt; accumulate in insulin-resistant tissues; and induce inflammation through the nuclear factor-κB (NF-Kβ)–TNF-α axis.100,101 Furthermore, ceramides correlate with coronary artery disease.102

Additional studies are needed to understand the relationships between lipid metabolism, prediabetes, and diabetes.

Ferritin and transferrin

Ferritin is an intracellular protein that stores and releases iron. Elevated serum ferritin and transferrin saturation have been strongly associated with increased risk of prediabetes and diabetes.103,104 Furthermore, a positive correlation with increased FPG and serum ferritin has been demonstrated.104 Iron contributes to IR through the production of highly active radical formation, damage to DNA and cell membrane integrity, β-cell oxidative stress resulting in decreased insulin secretory capacity,105 and interference with glucose uptake in skeletal muscles and adipocytes. Moreover, catalytic iron stimulates the formation of reactive oxidative species, hepatic dysfunction, and β-cell apoptosis,105,106 all of which contribute to IR. Dietary iron restriction or chelation prevents the development of diabetes and loss of β-cell function.105 The threshold levels of ferritin that correlate with IR are uncertain as these may vary with sex and age.107 Additional studies are needed to better understand ferritin and its role in prediabetes.

Mannose binding lectin serine peptidase, thrombospondin 1, and glycosylphosphatidylinositol-specific phospholipase D1

Mannose binding lectin-associated serine proteases are important for innate immune responses and activation of the lectin pathway of the complement system.108 MASP1, the most abundant serine protease of the complement lectin pathway, has a major role in the complement cascade.108 MASP1 has been shown to positively correlate with prediabetes, diabetes, as well as CVD. One study demonstrated that the onset of prediabetes and IR occurred earlier in those with increased MASP1 plasma levels.109 There was a positive association with elevated FPG and 2-hour glucose levels, but this weakened when adjusted for triacylglycerol levels. This suggests that triacylglycerol may mediate part of the association between MASP1 and HOMA-IR.109

Thrombospondin 1 (THBS1) and glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) are positively associated with prediabetes, whereas apolipoprotein A-IV (ApoA-IV) is inversely associated.109 THBS1 is a glycoprotein and member of the THB family, which has numerous functions such as cellular adhesion and migration regulation, cytoskeletal organization, cell proliferation and apoptosis, and cell-to-cell interactions.110 This matrix protein has been found to be associated with increased IR, which may be attributable to THB’s inflammatory properties, as well as increased 2-hour glucose levels and higher prediabetes prevalence.109

GPLD1, mainly produced in the liver, releases glycosylphosphatidylinositol-anchored membrane proteins.111 It is associated with serum lipoproteins and has been linked with diabetes and prediabetes.109,111 ApoA-IV, a component of chylomicrons, very low-density lipoprotein and HDL, has been shown to have a significant inverse relationship with prediabetes and diabetes.109 The exact role of ApoA-IV in vivo is unknown aside from regulating appetite and chylomicron production but it may have antioxidant and anti-inflammatory properties.112,113

There are limited studies describing the relationship between THBS1, GPLD1, and ApoA-IV and prediabetes; therefore, more data are required to better understand their respective roles.

Acyl-carnitine

Fatty acid oxidation (FAO) is a major source of cellular energy.114 L-carnitine plays a significant role in FAO as it transports activated long chain fatty acids (LCFA) from the cytosol into the mitochondria, a process referred to as the carnitine shuttle. Once inside, fatty acids undergo esterification to CoA. Carnitine palmitoyltransferase 1 exchanges the CoA moiety for carnitine resulting in acyl-carnitine production.115 Recently, serum levels of acyl-carnitines have been shown to be elevated in prediabetes.116,117 However, the essential role of acyl-carnitine in FAO and its mechanism in IR are uncertain. It has been proposed that impairment of FAO and dysregulated mitochondrial function result in accumulation of intermediary products such as acyl-carnitines. Thus, there is a mismatch of LCFA delivery and the tricarboxylic acid cycle.118 Furthermore, acyl-carnitines interact with NF-Kβ, which promotes inflammation and IR.118 However, there are few studies of acyl-carnitines in prediabetes.

MicroRNAs

MicroRNAs (miRNAs) are small, noncoding RNAs involved in post-transcriptional gene expression. These are pertinent to many biological and pathophysiological processes such as growth, development, differentiation, proliferation, and cell death. Recently, miRNAs have been studied in pre-diabetes,119121 several of which were increased including miR-192 and miR-193b. miR-192 regulates tumor protein p53, and miR-193b is important for the differentiation of brown adipocytes and inflammation reduction.122 Levels of both miRNAs were elevated in those with IFG and IGT. Furthermore, miR-192 and miR-193b have been correlated with Tg levels and the fatty liver index in animal models,120 which may be significant as a fatty liver can be associated with prediabetes.123 Moreover, exercise was shown to significantly decrease miR-192 and miR-193b concentrations.120

Other miRNAs significantly elevated in T2DM include miR-9, miR-29a, miR-30d, miR-34a, miR-124a2, miR-146a, and miR-375, all thought to play a role in β-cell function. These miRNAs were found to negatively regulate insulin expression, production, or secretion. However, no statistically significant increases were found in subjects with prediabetes, suggesting that there may be reversible pathophysiological processes that occur during prediabetes but not in T2DM.124

Additional miRNAs are decreased in prediabetes. Circulating levels of miR-126, abundant in endothelial cells playing a role in endothelial homeostasis and vascular integrity, are decreased in IGT/IFG and T2DM.125 miR-126 levels are increased with diet and exercise. miRNA-15a levels were also significantly lower in prediabetes, T2DM, and IFG/IGT.119 miR-15a is thought to regulate and promote insulin biosynthesis by inhibiting endogenous uncoupling protein-2 gene expression and increasing insulin secretion.126 Therefore, miR-15a has been suggested to play a significant role in β-cell function and insulin synthesis.

Inflammatory markers

Prediabetes and IR are characterized by a marked inflammatory state.127129 Biochemical markers of acute-phase reactants and inflammatory cytokines are elevated on the onset of T2DM and may even further increase with disease progression. These markers, such as C-reactive protein (CRP), white blood cell count, and fibrinogen, have been investigated as potential predictors for the development of T2DM such as in the Atherosclerosis Risk in Communities study.130

CRP and IL-6

CRP is the most widely studied inflammatory marker in CVD and its clinical use continues to evolve. CRP is primarily derived from IL-6-dependent hepatic biosynthesis and is a primary marker of the acute phase response. Many investigations have demonstrated elevated levels of both IL-6 and CRP among individuals with T2DM and IR. In the Women’s Health Study, a nationwide cohort of 27,628 women without diabetes mellitus (DM), CVD, or cancer at baseline, 188 women developed DM over a 4-year follow-up period.131 Median baseline levels of IL-6 and CRP were significantly higher among cases than controls. In addition, higher levels of IL-6 and CRP were associated with a greater risk of diabetes development. Relative risks of incident T2DM for increasing quartiles of IL-6 were 1.0, 2.5, 4.1, and 7.5, respectively (p<0.001 for trend), and for increasing quartiles of CRP were 1.0, 2.2, 8.7, and 15.7, respectively (p<0.001 for trend). While adjustment for BMI attenuated these relative risks, the results were still positive. These findings were similar when only including women with a baseline HbA1c of 6.0% (42 mmol/mol) or less and after adjustment for fasting insulin levels. This suggests that these inflammatory markers may be useful in identifying individuals at risk of developing T2DM.

The Insulin Resistance Atherosclerosis Study (IRAS) was a multicenter study of 1,625 individuals followed over 5.2 years.132 Individuals with prediabetes were defined as those developing diabetes during follow-up. Subjects with prediabetes who were also insulin resistant had elevated CRP levels compared to both insulin-sensitive individuals with prediabetes and non-diabetics. These differences were thought partly due to differences in body weight. Since subjects with prediabetes and IR were not hyperglycemic, subclinical inflammation could not be attributed solely to hyperglycemia. This hypothesis was supported in another study demonstrating that the glycemic index was not associated with CRP and risk of T2DM, suggesting that hyperglycemia per se is not the underlying mechanism linking diabetes and inflammation.133

The association between CRP and prediabetes has been confirmed in other studies. The Gutenberg Health Study was a prospective, observational single-center cohort study that included 15,010 adults, 1,425 of whom had prediabetes and 1,299 had diabetes according to HbA1c concentrations.134 CRP was shown to increase incrementally from normoglycemia to prediabetes (1.4 vs. 2.3 mg/L), whereas only a small increase was observed between subjects with prediabetes and diabetes (2.3 vs. 2.4 mg/L), suggesting that early immune activation plays a role in the onset of diabetes. Genetic variants in the innate immune system and inflammatory cascade also affect CRP and predisposition to T2DM.128,135

Other studies have further supported the association between increased levels of CRP and IL-6 and prediabetes.127,136 In a meta-analysis evaluating IL-6 with the risk for developing T2DM, the overall relative risk was 1.31 (95% confidence interval [CI] 1.17–1.46; p=0.000) per 1 log pg/mL increment in IL-6 levels.137 In another meta-analysis, these authors found that the overall risk of T2DM was 1.26 (95% CI 1.16–1.37; p=0.000) per 1 log mg/L increment in CRP levels.137 There may be differences in CRP as a predictor of diabetes in women compared to men.137 Interestingly, the meta-analysis showed that IL-6 was more strongly associated with T2DM than CRP, questioning the pathogenesis of subclinical inflammation in diabetes. CRP may therefore have a potential downstream role in this process but may not be the precipitating factor. However, in contrast to the latter findings, another study demonstrated that CRP was elevated in obesity and IR, whereas levels were low in insulin-sensitive or obese individuals.138

White blood cell count, fibrinogen, and hematological indices

White blood cell count and fibrinogen are also markers of immunity and inflammation that may have clinical relevance for disease progression and organ-specific complications in diabetes. Leukocytosis may also predict coronary heart disease.139 Therefore, the early identification of high-risk individuals may prevent the onset and/or progression of CVD. A high white blood cell count has been shown to predict worsening insulin action, insulin secretory function, and T2DM development in Pima Indians.140 Fibrinogen may contribute to atherosclerosis by affecting blood viscosity, platelet aggregation, and fibrin formation. Fibrinogen also modulates coagulation activation and fibrinolysis, and may enhance plaque progression. In the Gutenberg Health Study, fibrinogen levels were higher in prediabetes than in diabetes, although the reason for this finding is not clear.134

The neutrophil-lymphocyte ratio (NLR) and plateletlymphocyte ratio (PLR) are also indicators of subclinical inflammation. In a study of 110 adults, subjects were divided into four groups: NGT, IGT, newly diagnosed T2DM, and known T2DM without complications. NLR values were significantly higher in those with prediabetes, newly diagnosed diabetes, and known diabetes compared to the control group.141 PLR values were significantly lower in the prediabetes and newly diagnosed diabetes groups but higher in subjects with T2DM. Of note, NLR was higher in obese patients with diabetes than in those without diabetes. NLR has also been associated with both microvascular and macrovascular complications in diabetes.141144

Another investigation demonstrated that 1-hour post-load glucose levels were associated with a significantly higher white blood cell count and fibrinogen.145 Fiorentino et al showed that individuals with prediabetes had a significant increase in CRP, fibrinogen, and white blood cell count after adjusting for sex, age, smoking, and fasting and 1- and 2-hour post-load glucose levels.146

Plasminogen activator inhibitor-1

Tissue plasminogen activator-1 (PAI-1) is a marker of reduced fibrinolysis with decreased activity resulting in coagulation abnormalities.147 Changes in PAI-1 levels were shown to be an independent predictor of incident diabetes in IRAS.148

IL-18

Through oxidative mechanisms, hyperglycemia acutely increases cytokine concentrations including plasma IL-6, as already described, as well as TNF-α and IL-18.149 In a prospective case-cohort study, subjects with IL-18 in the highest quartile had a 70% increased risk of developing T2DM compared to those in the lowest quartile.149 IL-18 also increased with progression from prediabetes to diabetes in the Gutenberg study.134

IL-1 receptor antagonist

The IL-1 pathway may be induced by glucose and FFAs in the setting of overfeeding and contribute to an inflammatory state.150 The IL-1 receptor antagonist (IL-1RA), produced by adipocytes, is an anti-inflammatory marker elevated in prediabetes and diabetes, possibly as a reactive response to inflammation.134 In the Whitehall Study, a case-cohort study of 355 individuals with incident T2DM, an increase in IL-1RA in individuals with prediabetes occurred in parallel with decreasing insulin sensitivity, transiently increasing β-cell function, and 2-hour glucose levels, all of which occurred years before the occurrence of T2DM.151 Levels of IL-1RA were elevated 13 years before the diagnosis of T2DM. Of note, IL-1RA increased rapidly 6 years before diagnosis even after adjusting for obesity.

Patient-focused perspectives

According to the Centers for Disease Control and Prevention, as many as 90% of individuals with prediabetes are undiagnosed1 and therefore fail to receive guidance on lifestyle changes to prevent progression to T2DM. While HbA1c and glucose determinations for screening have been used in clinical practice for many years, each has deficiencies. As previously discussed, since HbA1c is insensitive for diagnosing acute and intermittent hyperglycemia and can be affected by various medical conditions and ethnicity, identification of other biomarkers would be of immense value. OGTT, while providing important information with regard to risk of developing T2DM that HbA1c or FPG do not, is associated with considerable variability, requires fasting, and is invasive and time consuming. However, intermediate time points during the OGTT (e.g., 30 or 60 minute post-load values) appear to predict progression to T2DM better than fasting, 2-hour post-load glucose or HbA1c levels, making this approach more favorable with the possibility of shortening the traditional 2-hour test.152 Additional studies are required to identify the most accurate biomarker(s), recognizing that a single determinant will likely have inherent limitations. Therefore, combining several biomarkers may more precisely predict those at high risk for developing prediabetes and subsequent progression to diabetes.

Conclusion and future perspectives

Categorical or absolute definitions of dysglycemia when applied to a continuous pathophysiologic process may inadvertently underestimate those at risk for progression. Progressively rising glucose levels, even within the so-called “normal range”, occur relatively late in the evolution to T2DM when β-cell function may already be reduced.153 Therefore, a vital need exists to identify more sensitive and precise biomarkers capable of predicting progression to dysglycemic states at the earliest time point when β-cell function is still relatively more optimal and may be more responsive to lifestyle modification. Combining biomarkers in a clinical setting may provide better sensitivity and specificity in predicting prediabetes and diabetes. Additional comparison studies of biomarkers will be required to ascertain their clinical utility. Furthermore, genetic studies assessing mutations may provide additional insight into associations with metabolic abnormalities.153,154

Footnotes

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Centers for Disease Control . National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States. Atlanta, GA: U.S. Department of Health and Human Services; 2014. [Google Scholar]
  • 2.International Diabetes Federation . IDF Diabetes Atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015. [Google Scholar]
  • 3.Bansal N. Prediabetes diagnosis and treatment: a review. World J Diabetes. 2015;6(2):296–303. doi: 10.4239/wjd.v6.i2.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003;46(1):3–19. doi: 10.1007/s00125-002-1009-0. [DOI] [PubMed] [Google Scholar]
  • 5.Gong Q, Gregg EW, Wang J, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2011;54(2):300–307. doi: 10.1007/s00125-010-1948-9. [DOI] [PubMed] [Google Scholar]
  • 6.Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2(6):474–480. doi: 10.1016/S2213-8587(14)70057-9. [DOI] [PubMed] [Google Scholar]
  • 7.Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350. doi: 10.1056/NEJM200105033441801. [DOI] [PubMed] [Google Scholar]
  • 8.Lindström J, Louheranta A, Mannelin M, et al. Finnish Diabetes Prevention Study Group The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26(12):3230–3236. doi: 10.2337/diacare.26.12.3230. [DOI] [PubMed] [Google Scholar]
  • 9.Diabetes Prevention Program Research Group. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–1686. doi: 10.1016/S0140-6736(09)61457-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sjöström CD, Lissner L, Wedel H, Sjöström L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7(5):477–484. doi: 10.1002/j.1550-8528.1999.tb00436.x. [DOI] [PubMed] [Google Scholar]
  • 11.Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29(5):1130–1139. doi: 10.2337/diacare.2951130. [DOI] [PubMed] [Google Scholar]
  • 12.Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55(5):1430–1435. doi: 10.2337/db05-1200. [DOI] [PubMed] [Google Scholar]
  • 13.Festa A, D’Agostino R, Jr, Hanley AJ, Karter AJ, Saad MF, Haffner SM. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes. 2004;53(6):1549–1555. doi: 10.2337/diabetes.53.6.1549. [DOI] [PubMed] [Google Scholar]
  • 14.American Diabetes Association Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl 1):S14–S80. doi: 10.2337/dc14-S014. [DOI] [PubMed] [Google Scholar]
  • 15.American Diabetes Association (2). Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl 1):S8–S16. doi: 10.2337/dc15-S005. [DOI] [PubMed] [Google Scholar]
  • 16.World Health Organization . Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organization; 2006. 2013. [Google Scholar]
  • 17.Bookchin RM, Gallop PM. Structure of hemoglobin AIc: nature of the N-terminal beta chain blocking group. Biochem Biophys Res Commun. 1968;32(1):86–93. doi: 10.1016/0006-291x(68)90430-0. [DOI] [PubMed] [Google Scholar]
  • 18.Pfister R, Sharp SJ, Luben R, Khaw KT, Wareham NJ. No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population. Diabetologia. 2011;54(8):2025–2032. doi: 10.1007/s00125-011-2162-0. [DOI] [PubMed] [Google Scholar]
  • 19.White NH, Sun W, Cleary PA, et al. DCCT-EDIC Research Group Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59(5):1244–1253. doi: 10.2337/db09-1216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Diabetes Control and Complications Trial Research Group. Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. doi: 10.1056/NEJM199309303291401. [DOI] [PubMed] [Google Scholar]
  • 21.Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. doi: 10.1136/bmj.321.7258.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20(7):1183–1197. doi: 10.2337/diacare.20.7.1183. [DOI] [PubMed] [Google Scholar]
  • 23.Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C. Diabetes Care. 2011;34(Suppl 2):S184–S190. doi: 10.2337/dc11-s216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care. 2010;33(10):2184–2189. doi: 10.2337/dc10-0433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS) Diabetes Care. 2010;33(9):2104–2109. doi: 10.2337/dc10-0679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zhou X, Pang Z, Gao W, et al. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. Diabetes Care. 2010;33(3):545–550. doi: 10.2337/dc09-1410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.James C, Bullard KM, Rolka DB, et al. Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care. 2011;34(2):387–391. doi: 10.2337/dc10-1314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Guo F, Moellering DR, Garvey WT. Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. Metab Syndr Relat Disord. 2014;12(5):258–268. doi: 10.1089/met.2013.0128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Malkani S, Mordes JP. Implications of using hemoglobin A1C for diagnosing diabetes mellitus. Am J Med. 2011;124(5):395–401. doi: 10.1016/j.amjmed.2010.11.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Christensen DL, Witte DR, Kaduka L, et al. Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care. 2010;33(3):580–582. doi: 10.2337/dc09-1843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Herman WH, Ma Y, Uwaifo G, et al. Diabetes Prevention Program Research Group Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007;30(10):2453–2457. doi: 10.2337/dc06-2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Li J, Ma H, Na L, et al. Increased hemoglobin A1c threshold for pre-diabetes remarkably improving the agreement between A1c and oral glucose tolerance test criteria in obese population. J Clin Endocrinol Metab. 2015;100(5):1997–2005. doi: 10.1210/jc.2014-4139. [DOI] [PubMed] [Google Scholar]
  • 33.Pani LN, Korenda L, Meigs JB, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001–2004. Diabetes Care. 2008;31(10):1991–1996. doi: 10.2337/dc08-0577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Herman WH. Do race and ethnicity impact hemoglobin A1c independent of glycemia? J Diabetes Sci Technol. 2009;3(4):656–660. doi: 10.1177/193229680900300406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48(3):436–472. [PubMed] [Google Scholar]
  • 36.Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014;29(2):388–394. doi: 10.1007/s11606-013-2595-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lee JE. Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol. Ann Pediatr Endocrinol Metab. 2015;20(2):74–78. doi: 10.6065/apem.2015.20.2.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Malmström H, Walldius G, Grill V, Jungner I, Gudbjörnsdottir S, Hammar N. Fructosamine is a useful indicator of hyperglycaemia and glucose control in clinical and epidemiological studies–cross-sectional and longitudinal experience from the AMORIS cohort. PLoS One. 2014;9(10):e111463. doi: 10.1371/journal.pone.0111463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47(2):153–163. [PubMed] [Google Scholar]
  • 40.Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011;57(6):e1–e47. doi: 10.1373/clinchem.2010.161596. [DOI] [PubMed] [Google Scholar]
  • 41.Ribeiro RT, Macedo MP, Raposo JF. HbA1c, fructosamine, and glycated albumin in the detection of dysglycaemic conditions. Curr Diabetes Rev. 2016;12(1):14–19. doi: 10.2174/1573399811666150701143112. [DOI] [PubMed] [Google Scholar]
  • 42.Austin GE, Wheaton R, Nanes MS, Rubin J, Mullins RE. Usefulness of fructosamine for monitoring outpatients with diabetes. Am J Med Sci. 1999;318(5):316–323. doi: 10.1097/00000441-199911000-00006. [DOI] [PubMed] [Google Scholar]
  • 43.Weerasekera DS, Peiris H. The value of serum fructosamine in comparison with oral glucose tolerance test (OGTT) as a screening test for detection of gestational diabetes mellitus. J Obstet Gynaecol. 2000;20(2):136–138. doi: 10.1080/01443610062878. [DOI] [PubMed] [Google Scholar]
  • 44.Schleicher ED, Olgemöller B, Wiedenmann E, Gerbitz KD. Specific glycation of albumin depends on its half-life. Clin Chem. 1993;39(4):625–628. [PubMed] [Google Scholar]
  • 45.Selvin E, Francis LM, Ballantyne CM, et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. 2011;34(4):960–967. doi: 10.2337/dc10-1945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Rodríguez-Segade S, Rodríguez J, Camiña F. Corrected Fructosamine improves both correlation with HbA1C and diagnostic performance. Clin Biochem. 2017;50(3):110–115. doi: 10.1016/j.clinbiochem.2016.10.014. [DOI] [PubMed] [Google Scholar]
  • 47.Chan CL, Pyle L, Kelsey M, Newnes L, Zeitler PS, Nadeau KJ. Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia – 1,5-anhydroglucitol, fructosamine, and glycated albumin. Pediatr Diabetes. 2016;17(3):206–211. doi: 10.1111/pedi.12258. [DOI] [PubMed] [Google Scholar]
  • 48.Malkan UY, Gunes G, Corakci A. Rational diagnoses of diabetes: the comparison of 1,5-anhydroglucitol with other glycemic markers. Springerplus. 2015;4:587. doi: 10.1186/s40064-015-1389-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Sumner AE, Duong MT, Aldana PC, et al. A1C combined with glycated albumin improves detection of prediabetes in Africans: the Africans in America Study. Diabetes Care. 2016;39(2):271–277. doi: 10.2337/dc15-1699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Danese E, Montagnana M, Nouvenne A, Lippi G. Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. J Diabetes Sci Technol. 2015;9(2):169–176. doi: 10.1177/1932296814567227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Selvin E, Rawlings AM, Grams M, et al. Prognostic utility of fructosamine and glycated albumin for incident diabetes and microvascular complications. Lancet Diabetes Endocrinol. 2014;2(4):279–288. doi: 10.1016/S2213-8587(13)70199-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Wu WC, Ma WY, Wei JN, et al. Serum glycated albumin to guide the diagnosis of diabetes mellitus. PLoS One. 2016;11(1):e0146780. doi: 10.1371/journal.pone.0146780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Furusyo N, Koga T, Ai M, et al. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS) Diabetologia. 2011;54(12):3028–3036. doi: 10.1007/s00125-011-2310-6. [DOI] [PubMed] [Google Scholar]
  • 54.Selvin E, Rawlings AM, Lutsey PL, et al. Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. Circulation. 2015;132(4):269–277. doi: 10.1161/CIRCULATIONAHA.115.015415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Shima K, Abe F, Chikakiyo H, Ito N. The relative value of glycated albumin, hemoglobin A1c and fructosamine when screening for diabetes mellitus. Diabetes Res Clin Pract. 1989;7(4):243–250. doi: 10.1016/0168-8227(89)90011-9. [DOI] [PubMed] [Google Scholar]
  • 56.Okada T, Nakao T, Matsumoto H, Yamanaka T, Nagaoka Y, Tamekuni T. Influence of age and nutritional status on glycated albumin values in hemodialysis patients. Intern Med. 2009;48(17):1495–1499. doi: 10.2169/internalmedicine.48.2301. [DOI] [PubMed] [Google Scholar]
  • 57.Bulló M, García-Lorda P, Megias I, Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obesity Res. 2003;11(4):525–531. doi: 10.1038/oby.2003.74. [DOI] [PubMed] [Google Scholar]
  • 58.Koga M, Hirata T, Kasayama S, Ishizaka Y, Yamakado M. Body mass index negatively regulates glycated albumin through insulin secretion in patients with type 2 diabetes mellitus. Clin Chim Acta. 2015;438:19–23. doi: 10.1016/j.cca.2014.07.035. [DOI] [PubMed] [Google Scholar]
  • 59.Ma XJ, Pan JM, Bao YQ, et al. Combined assessment of glycated albumin and fasting plasma glucose improves the detection of diabetes in Chinese subjects. Clin Exp Pharmacol Physiol. 2010;37(10):974–979. doi: 10.1111/j.1440-1681.2010.05417.x. [DOI] [PubMed] [Google Scholar]
  • 60.Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther. 2003;5(3):355–363. doi: 10.1089/152091503765691839. [DOI] [PubMed] [Google Scholar]
  • 61.Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract. 1994;24(Suppl):S261–S268. doi: 10.1016/0168-8227(94)90259-3. [DOI] [PubMed] [Google Scholar]
  • 62.Yamanouchi T, Akanuma H, Nakamura T, Akaoka I, Akanuma Y. Reduction of plasma 1,5-anhydroglucitol (1-deoxyglucose) concentration in diabetic patients. Diabetologia. 1988;31(1):41–45. doi: 10.1007/BF00279131. [DOI] [PubMed] [Google Scholar]
  • 63.Yamanouchi T, Minoda S, Yabuuchi M, et al. Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes. 1989;38(6):723–729. doi: 10.2337/diab.38.6.723. [DOI] [PubMed] [Google Scholar]
  • 64.Wang Y, Yuan Y, Zhang Y, et al. Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes. Acta Diabetol. 2017;54(5):425–431. doi: 10.1007/s00592-016-0944-z. [DOI] [PubMed] [Google Scholar]
  • 65.Kim WJ, Park CY. 1,5-Anhydroglucitol in diabetes mellitus. Endocrine. 2013;43(1):33–40. doi: 10.1007/s12020-012-9760-6. [DOI] [PubMed] [Google Scholar]
  • 66.Balis DA, Tong C, Meininger G. Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol. J Diabetes. 2014;6(4):378–380. doi: 10.1111/1753-0407.12116. [DOI] [PubMed] [Google Scholar]
  • 67.Hasslacher C, Kulozik F. Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I–III: a comparative study with HbA1c and glycated albumin. J Diabetes. 2016;8(5):712–719. doi: 10.1111/1753-0407.12354. [DOI] [PubMed] [Google Scholar]
  • 68.Tabák AG, Carstensen M, Witte DR, et al. Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study. Diabetes Care. 2012;35(12):2540–2547. doi: 10.2337/dc11-2263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Jiang Y, Owei I, Wan J, Ebenibo S, Dagogo-Jack S. Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study. BMJ Open Diabetes Res Care. 2016;4(1):e000194. doi: 10.1136/bmjdrc-2016-000194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Stefan N, Sun Q, Fritsche A, et al. Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies. PLoS One. 2014;9(3):e92238. doi: 10.1371/journal.pone.0092238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Pal D, Dasgupta S, Kundu R, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012;18(8):1279–1285. doi: 10.1038/nm.2851. [DOI] [PubMed] [Google Scholar]
  • 72.Sun Q, Jiménez MC, Townsend MK, et al. Plasma levels of fetuin-A and risk of coronary heart disease in US women: the Nurses’ Health Study. J Am Heart Assoc. 2014;3(3):e000939. doi: 10.1161/JAHA.114.000939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Weikert C, Stefan N, Schulze MB, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008;118(24):2555–2562. doi: 10.1161/CIRCULATIONAHA.108.814418. [DOI] [PubMed] [Google Scholar]
  • 74.Aroner SA, St-Jules DE, Mukamal KJ, et al. Fetuin-A, glycemic status, and risk of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2016;248:224–229. doi: 10.1016/j.atherosclerosis.2016.03.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Felig P, Marliss E, Cahill GF., Jr Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969;281(15):811–816. doi: 10.1056/NEJM196910092811503. [DOI] [PubMed] [Google Scholar]
  • 76.Gall WE, Beebe K, Lawton KA, et al. RISC Study Group alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One. 2010;5(5):e10883. doi: 10.1371/journal.pone.0010883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9(4):311–326. doi: 10.1016/j.cmet.2009.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Huffman KM, Shah SH, Stevens RD, et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care. 2009;32(9):1678–1683. doi: 10.2337/dc08-2075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Chen T, Ni Y, Ma X, et al. Branched-chain and aromatic amino acid profiles and diabetes risk in Chinese populations. Sci Rep. 2016;6:20594. doi: 10.1038/srep20594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Knebel B, Strassburger K, Szendroedi J, et al. German Diabetes Study Group Specific metabolic profiles and their relationship to insulin resistance in recent-onset type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2016;101(5):2130–2140. doi: 10.1210/jc.2015-4133. [DOI] [PubMed] [Google Scholar]
  • 81.Wang TJ, Ngo D, Psychogios N, et al. 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest. 2013;123(10):4309–4317. doi: 10.1172/JCI64801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–453. doi: 10.1038/nm.2307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.El-Khairy L, Ueland PM, Nygård O, Refsum H, Vollset SE. Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: the Hordaland Homocysteine Study. Am J Clin Nutr. 1999;70(6):1016–1024. doi: 10.1093/ajcn/70.6.1016. [DOI] [PubMed] [Google Scholar]
  • 84.Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615. doi: 10.1038/msb.2012.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Guasch-Ferré M, Hruby A, Toledo E, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care. 2016;39(5):833–846. doi: 10.2337/dc15-2251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Sekhar RV, McKay SV, Patel SG, et al. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care. 2011;34(1):162–167. doi: 10.2337/dc10-1006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One. 2010;5(12):e15234. doi: 10.1371/journal.pone.0015234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Landaas S. The formation of 2-hydroxybutyric acid in experimental animals. Clin Chim Acta. 1975;58(1):23–32. doi: 10.1016/0009-8981(75)90481-7. [DOI] [PubMed] [Google Scholar]
  • 89.Rosalki SB, Wilkinson JH. Reduction of alpha-ketobutyrate by human serum. Nature. 1960;188:1110–1111. doi: 10.1038/1881110a0. [DOI] [PubMed] [Google Scholar]
  • 90.Lord RS, Bralley JA. Clinical applications of urinary organic acids. Part I: Detoxification markers. Altern Med Rev. 2008;13(3):205–215. [PubMed] [Google Scholar]
  • 91.Cobb J, Eckhart A, Motsinger-Reif A, Carr B, Groop L, Ferrannini E. α-Hydroxybutyric acid is a selective metabolite biomarker of impaired glucose tolerance. Diabetes Care. 2016;39(6):988–995. doi: 10.2337/dc15-2752. [DOI] [PubMed] [Google Scholar]
  • 92.Cunningham TJ, Yao L, Lucena A. Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines’ unexpected therapeutic properties. J Inflamm (Lond) 2008;5:17. doi: 10.1186/1476-9255-5-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Cobb J, Gall W, Adam KP, et al. A novel fasting blood test for insulin resistance and prediabetes. J Diabetes Sci Technol. 2013;7(1):100–110. doi: 10.1177/193229681300700112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Dotevall A, Johansson S, Wilhelmsen L, Rosengren A. Increased levels of triglycerides, BMI and blood pressure and low physical activity increase the risk of diabetes in Swedish women. A prospective 18-year follow-up of the BEDA study. Diabet Med. 2004;21(6):615–622. doi: 10.1111/j.1464-5491.2004.01189.x. [DOI] [PubMed] [Google Scholar]
  • 95.Ding L, Song A, Dai M, et al. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population. J Lipid Res. 2015;56(4):920–926. doi: 10.1194/jlr.P049015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Shimodaira M, Niwa T, Nakajima K, Kobayashi M, Hanyu N, Nakayama T. Serum triglyceride levels correlated with the rate of change in insulin secretion over two years in prediabetic subjects. Ann Nutr Metab. 2014;64(1):38–43. doi: 10.1159/000360012. [DOI] [PubMed] [Google Scholar]
  • 97.Filippatos TD, Rizos EC, Tsimihodimos V, Gazi IF, Tselepis AD, Elisaf MS. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A2 in subjects with prediabetes. Lipids. 2013;48(6):547–555. doi: 10.1007/s11745-013-3787-1. [DOI] [PubMed] [Google Scholar]
  • 98.Meikle PJ, Wong G, Barlow CK, et al. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS One. 2013;8(9):e74341. doi: 10.1371/journal.pone.0074341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Haus JM, Kashyap SR, Kasumov T, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes. 2009;58(2):337–343. doi: 10.2337/db08-1228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res. 2006;45(1):42–72. doi: 10.1016/j.plipres.2005.11.002. [DOI] [PubMed] [Google Scholar]
  • 101.Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008;29(4):381–402. doi: 10.1210/er.2007-0025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Jiang XC, Paultre F, Pearson TA, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2000;20(12):2614–2618. doi: 10.1161/01.atv.20.12.2614. [DOI] [PubMed] [Google Scholar]
  • 103.Aregbesola A, Virtanen JK, Voutilainen S, et al. Serum ferritin and glucose homeostasis: change in the association by glycaemic state. Diabetes Metab Res Rev. 2015;31(5):507–514. doi: 10.1002/dmrr.2628. [DOI] [PubMed] [Google Scholar]
  • 104.Sharifi F, Nasab NM, Zadeh HJ. Elevated serum ferritin concentrations in prediabetic subjects. Diab Vasc Dis Res. 2008;5(1):15–18. doi: 10.3132/dvdr.2008.003. [DOI] [PubMed] [Google Scholar]
  • 105.Cooksey RC, Jones D, Gabrielsen S, et al. Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep−/−) mouse. Am J Physiol Endocrinol Metab. 2010;298(6):E1236–E1243. doi: 10.1152/ajpendo.00022.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Huang J, Jones D, Luo B, et al. Iron overload and diabetes risk: a shift from glucose to Fatty Acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis. Diabetes. 2011;60(1):80–87. doi: 10.2337/db10-0593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J. 2000;140(1):98–104. doi: 10.1067/mhj.2000.106646. [DOI] [PubMed] [Google Scholar]
  • 108.Dobó J, Schroeder V, Jenny L, Cervenak L, Závodszky P, Gál P. Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation. Mol Immunol. 2014;61(2):69–78. doi: 10.1016/j.molimm.2014.05.013. [DOI] [PubMed] [Google Scholar]
  • 109.von Toerne C, Huth C, de Las Heras Gala T, et al. MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study. Diabetologia. 2016;59(9):1882–1892. doi: 10.1007/s00125-016-4024-2. [DOI] [PubMed] [Google Scholar]
  • 110.Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol. 2000;12(5):634–640. doi: 10.1016/s0955-0674(00)00143-5. [DOI] [PubMed] [Google Scholar]
  • 111.Hoener MC, Brodbeck U. Phosphatidylinositol-glycan-specific phospholipase D is an amphiphilic glycoprotein that in serum is associated with high-density lipoproteins. Eur J Biochem. 1992;206(3):747–757. doi: 10.1111/j.1432-1033.1992.tb16981.x. [DOI] [PubMed] [Google Scholar]
  • 112.Wang F, Kohan AB, Lo CM, Liu M, Howles P, Tso P. Apolipoprotein A-IV: a protein intimately involved in metabolism. J Lipid Res. 2015;56(8):1403–1418. doi: 10.1194/jlr.R052753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Green PH, Glickman RM, Riley JW, Quinet E. Human apolipoprotein A-IV: Intestinal origin and distribution in plasma. J Clin Invest. 1980;65(4):911–919. doi: 10.1172/JCI109745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Eaton S. Control of mitochondrial beta-oxidation flux. Prog Lipid Res. 2002;41(3):197–239. doi: 10.1016/s0163-7827(01)00024-8. [DOI] [PubMed] [Google Scholar]
  • 115.Ramsay RR, Gandour RD, van der Leij FR. Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta. 2001;1546(1):21–43. doi: 10.1016/s0167-4838(01)00147-9. [DOI] [PubMed] [Google Scholar]
  • 116.Zhang X, Zhang C, Chen L, Han X, Ji L. Human serum acylcarnitine profiles in different glucose tolerance states. Diabetes Res Clin Pract. 2014;104(3):376–382. doi: 10.1016/j.diabres.2014.04.013. [DOI] [PubMed] [Google Scholar]
  • 117.Mai M, Tönjes A, Kovacs P, Stumvoll M, Fiedler GM, Leichtle AB. Serum levels of acylcarnitines are altered in prediabetic conditions. PLoS One. 2013;8(12):e82459. doi: 10.1371/journal.pone.0082459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Adams SH, Hoppel CL, Lok KH, et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr. 2009;139(6):1073–1081. doi: 10.3945/jn.108.103754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Al-Kafaji G, Al-Mahroos G, Alsayed NA, Hasan ZA, Nawaz S, Bakhiet M. Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes. Mol Med Rep. 2015;12(5):7485–7490. doi: 10.3892/mmr.2015.4416. [DOI] [PubMed] [Google Scholar]
  • 120.Párrizas M, Brugnara L, Esteban Y, et al. Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention. J Clin Endocrinol Metab. 2015;100(3):E407–E415. doi: 10.1210/jc.2014-2574. [DOI] [PubMed] [Google Scholar]
  • 121.Yang Z, Chen H, Si H, et al. Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol. 2014;51(5):823–831. doi: 10.1007/s00592-014-0617-8. [DOI] [PubMed] [Google Scholar]
  • 122.Sun L, Xie H, Mori MA, et al. Mir193b-365 is essential for brown fat differentiation. Nat Cell Biol. 2011;13(8):958–965. doi: 10.1038/ncb2286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Zelber-Sagi S, Lotan R, Shibolet O, et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 2013;33(9):1406–1412. doi: 10.1111/liv.12200. [DOI] [PubMed] [Google Scholar]
  • 124.Kong L, Zhu J, Han W, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2011;48(1):61–69. doi: 10.1007/s00592-010-0226-0. [DOI] [PubMed] [Google Scholar]
  • 125.Liu Y, Gao G, Yang C, et al. The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. Int J Mol Sci. 2014;15(6):10567–10577. doi: 10.3390/ijms150610567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Sun LL, Jiang BG, Li WT, Zou JJ, Shi YQ, Liu ZM. MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res Clin Pract. 2011;91(1):94–100. doi: 10.1016/j.diabres.2010.11.006. [DOI] [PubMed] [Google Scholar]
  • 127.Maschirow L, Khalaf K, Al-Aubaidy HA, Jelinek HF. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes–Biomarkers as a possible tool for early disease detection for rural screening. Clin Biochem. 2015;48(9):581–585. doi: 10.1016/j.clinbiochem.2015.02.015. [DOI] [PubMed] [Google Scholar]
  • 128.Arora P, Garcia-Bailo B, Dastani Z, et al. Genetic polymorphisms of innate immunity-related inflammatory pathways and their association with factors related to type 2 diabetes. BMC Med Genet. 2011;12:95. doi: 10.1186/1471-2350-12-95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107. doi: 10.1038/nri2925. [DOI] [PubMed] [Google Scholar]
  • 130.Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353(9165):1649–1652. doi: 10.1016/s0140-6736(99)01046-6. [DOI] [PubMed] [Google Scholar]
  • 131.Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334. doi: 10.1001/jama.286.3.327. [DOI] [PubMed] [Google Scholar]
  • 132.Festa A, Hanley AJ, Tracy RP, D’Agostino R, Jr, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation. 2003;108(15):1822–1830. doi: 10.1161/01.CIR.0000091339.70120.53. [DOI] [PubMed] [Google Scholar]
  • 133.van Woudenbergh GJ, Kuijsten A, Sijbrands EJ, Hofman A, Witteman JC, Feskens EJ. Glycemic index and glycemic load and their association with C-reactive protein and incident type 2 diabetes. J Nutr Metab. 2011;2011:623076. doi: 10.1155/2011/623076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Grossmann V, Schmitt VH, Zeller T, et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care. 2015;38(7):1356–1364. doi: 10.2337/dc14-3008. [DOI] [PubMed] [Google Scholar]
  • 135.Dehghan A, Kardys I, de Maat MP, et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes. 2007;56(3):872–878. doi: 10.2337/db06-0922. [DOI] [PubMed] [Google Scholar]
  • 136.Wang Z, Shen XH, Feng WM, Ye GF, Qiu W, Li B. Analysis of inflammatory mediators in prediabetes and newly diagnosed type 2 diabetes patients. J Diabetes Res. 2016;2016:7965317. doi: 10.1155/2016/7965317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36(1):166–175. doi: 10.2337/dc12-0702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138.McLaughlin T, Abbasi F, Lamendola C, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002;106(23):2908–2912. doi: 10.1161/01.cir.0000041046.32962.86. [DOI] [PubMed] [Google Scholar]
  • 139.Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol. 2004;44(10):1945–1956. doi: 10.1016/j.jacc.2004.07.056. [DOI] [PubMed] [Google Scholar]
  • 140.Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51(2):455–461. doi: 10.2337/diabetes.51.2.455. [DOI] [PubMed] [Google Scholar]
  • 141.Mertoglu C, Gunay M. Neutrophil-Lymphocyte ratio and Platelet-Lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. Diabetes Metab Syndr. 2016 Dec 12; doi: 10.1016/j.dsx.2016.12.021. Epub. [DOI] [PubMed] [Google Scholar]
  • 142.Wang RT, Zhang JR, Li Y, Liu T, Yu KJ. Neutrophil-Lymphocyte ratio is associated with arterial stiffness in diabetic retinopathy in type 2 diabetes. J Diabetes Complications. 2015;29(2):245–249. doi: 10.1016/j.jdiacomp.2014.11.006. [DOI] [PubMed] [Google Scholar]
  • 143.Verdoia M, Schaffer A, Barbieri L, et al. Novara Atherosclerosis Study Group (NAS) Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease. Diabetes Metab. 2015;41(4):304–311. doi: 10.1016/j.diabet.2015.01.001. [DOI] [PubMed] [Google Scholar]
  • 144.Demirtas L, Degirmenci H, Akbas EM, et al. Association of hematological indicies with diabetes, impaired glucose regulation and micro-vascular complications of diabetes. Int J Clin Exp Med. 2015;8(7):11420–11427. [PMC free article] [PubMed] [Google Scholar]
  • 145.Bardini G, Dicembrini I, Cresci B, Rotella CM. Inflammation markers and metabolic characteristics of subjects with 1-h plasma glucose levels. Diabetes Care. 2010;33(2):411–413. doi: 10.2337/dc09-1342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146.Fiorentino TV, Hribal ML, Perticone M, et al. Unfavorable inflammatory profile in adults at risk of type 2 diabetes identified by hemoglobin A1c levels according to the American Diabetes Association criteria. Acta Diabetol. 2015;52(2):349–356. doi: 10.1007/s00592-014-0647-2. [DOI] [PubMed] [Google Scholar]
  • 147.Festa A, D’Agostino R, Jr, Tracy RP, Haffner SM, Insulin Resistance Atherosclerosis Study Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131–1137. doi: 10.2337/diabetes.51.4.1131. [DOI] [PubMed] [Google Scholar]
  • 148.Festa A, D’Agostino R, Jr, Mykkänen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS) Arterioscler Thromb Vasc Biol. 1999;19(3):562–568. doi: 10.1161/01.atv.19.3.562. [DOI] [PubMed] [Google Scholar]
  • 149.Thorand B, Kolb H, Baumert J, et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MON-ICA/KORA Augsburg Study, 1984–2002. Diabetes. 2005;54(10):2932–2938. doi: 10.2337/diabetes.54.10.2932. [DOI] [PubMed] [Google Scholar]
  • 150.Donath MY. Inflammation as a sensor of metabolic stress in obesity and type 2 diabetes. Endocrinology. 2011;152(11):4005–4006. doi: 10.1210/en.2011-1691. [DOI] [PubMed] [Google Scholar]
  • 151.Carstensen M, Herder C, Kivimäki M, et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes. 2010;59(5):1222–1227. doi: 10.2337/db09-1199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Bergman M, Jagannathan R, Buysschaert M, et al. Reducing the prevalence of dysglycemia: is the time ripe to test the effectiveness of intervention in high-risk individuals with elevated 1 h post-load glucose levels? Endocrine. 2017;55(3):697–701. doi: 10.1007/s12020-017-1236-2. [DOI] [PubMed] [Google Scholar]
  • 153.Bergman M. The Early Diabetes Intervention Program--is early actually late? Diabetes Metab Res Rev. 2014;30(8):654–658. doi: 10.1002/dmrr.2563. [DOI] [PubMed] [Google Scholar]
  • 154.Bueno AC, Sun K, Martins CS, et al. A novel ADIPOQ mutation (p.M40K) impairs assembly of high-molecular-weight adiponectin and is associated with early-onset obesity and metabolic syndrome. J Clin Endocrinol Metab. 2014;99(4):E683–E693. doi: 10.1210/jc.2013-3009. [DOI] [PubMed] [Google Scholar]
  • 155.Aekplakorn W, Tantayotai V, Numsangkul S, et al. Detecting Pre-diabetes and Diabetes: Agreement between Fasting Plasma Glucose and Oral Glucose Tolerance Test in Thai Adults. J Diabetes Res. 2015;2015:396505. doi: 10.1155/2015/396505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 156.Gall WE, Beebe K, Lawton KA, et al. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One. 2010;5(5):e10883. doi: 10.1371/journal.pone.0010883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157.Suzuki T, Imai J, Yamada T, et al. Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway. Diabetes. 2011;60(2):537–547. doi: 10.2337/db10-0796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158.Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm. 2009;80:613–633. doi: 10.1016/S0083-6729(08)00621-3. [DOI] [PubMed] [Google Scholar]

Articles from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy are provided here courtesy of Dove Press

RESOURCES